| Literature DB >> 28146116 |
Paride Papadia1, Fabrizio Barozzi2, James D Hoeschele3, Gabriella Piro4, Nicola Margiotta5, Gian-Pietro Di Sansebastiano6.
Abstract
The immediate visual comparison of platinum chemotherapeutics' effects in eukaryotic cells using accessible plant models of transgenic Arabidopsis thaliana is reported. The leading anticancer drug cisplatin, a third generation drug used for colon cancer, oxaliplatin and kiteplatin, promising Pt-based anticancer drugs effective against resistant lines, were administered to transgenic A. thaliana plants monitoring their effects on cells from different tissues. The transgenic plants' cell cytoskeletons were labelled by the green fluorescent protein (GFP)-tagged microtubule-protein TUA6 (TUA6-GFP), while the vacuolar organization was evidenced by two soluble chimerical GFPs (GFPChi and AleuGFP) and one transmembrane GFP-tagged tonoplast intrinsic protein 1-1 (TIP1.1-GFP). The three drugs showed easily recognizable effects on plant subcellular organization, thereby providing evidence for a differentiated drug targeting. Genetically modified A. thaliana are confirmed as a possible rapid and low-cost screening tool for better understanding the mechanism of action of human anticancer drugs.Entities:
Keywords: cisplatin; cytoskeleton; kiteplatin; oxaliplatin; transgenic Arabidopsis; vacuoles
Mesh:
Substances:
Year: 2017 PMID: 28146116 PMCID: PMC5343842 DOI: 10.3390/ijms18020306
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The three platinum-based anticancer compounds investigated in this work.
Figure 2Fluorescent patterns of green fluorescent protein (GFP)-tagged microtubule-protein TUA6 (TUA6-GFP) microtubules marker in elongated petiole cells of transgenic Arabidopsis thaliana. (A) Normal fluorescent pattern of TUA6-GFP as observed after treatment with low drug doses (here 0.1 mg/L, 0.26 µM kiteplatin); (B) Perturbed microtubules after treatment with 1 mg/L, 2.5 µM, oxaliplatin; (C) Weak perturbation of microtubules orientation after treatment with 5 mg/L, 13 µM, kiteplatin; (D) Strong alteration due to treatment with 200 mg/L kiteplatin; (E) Clear alteration of TUA6-GFP distribution after treatment with 1 mg/L (3 µM); and (F) 200 mg/L (67 µM) cisplatin. Scale bar: 20 µm.
Figure 3Fluorescent patterns of GFP-tagged tonoplast intrinsic protein 1-1 (TIP1.1-GFP) tonoplast marker, in different tissues. (A) Confocal sections projection of the young root at the level of trichoblast differentiation in control conditions; (B) Single confocal section of hypocotyl’s cells in control conditions. Scale bar: 20 µm.
Figure 4Fluorescent patterns of AleuGFP vacuolar marker, in different tissues. (A) Single confocal section of hypocotyl’s cells in control; (B) Hypocotyl’s cells treated with 5 mg/L (13 µM) kiteplatin; (C) 5 mg/L (13 µM) oxaliplatin or (D) 5 mg/L (17 µM) cisplatin. Long yellow arrows indicate endoplasmic reticulum (ER) bodies while short green arrows indicate different large round-shaped compartments. Four confocal sections projection of young root at the end of elongation stage (emerging trichoblasts) in (E) control conditions or treated with (F) 10 mg/L (26 µM) kiteplatin; (G) 10 mg/L (25 µM) oxaliplatin; or (H) 10 mg/L (33 µM) cisplatin. Scale bar: 20 µm.
Figure 5Fluorescent patterns of GFPChi vacuolar marker, in different tissues. Single confocal section of hypocotyl’s cells in (A) control; hypocotyl’s cells treated with (B) 5 mg/L (13 µM) kiteplatin; (C) 5 mg/L (13 µM) oxaliplatin; or (D) 5 mg/L (17 µM) cisplatin. Long yellow arrows indicate ER bodies while short green arrows indicate different large round-shaped compartments and long red arrows indicate pre-vacuolar-compartments (PVCs). Four confocal sections projection of young root at the end of elongation stage (emerging trichoblasts) in (E) control or (F) treated with 10 mg/L (26 µM) kiteplatin; (G) 10 mg/L (25 µM) oxaliplatin; or (H) 10 mg/L (33 µM) cisplatin. Scale bar: 20 µm.